Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics^TM, a new class of drugs for the treatment of multiple diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

We have a robust clinical-stage product pipeline that includes multiple mid-stage product candidates, as well as preclinical programs. Our most advanced product candidates are in development for residual symptoms in schizophrenia, attention deficit/hyperactivity disorder (inattentive-predominant), Alzheimer’s disease and inflammatory disorders.

Targacept is located in Winston-Salem, North Carolina.

Targacept has several product candidates in clinical development. View our pipeline to learn more. On May 2, 2011, The Scientist magazine announced the winners of its 9th annual "Best Places to Work in Industry" survey... more..... Watch the animation to find out how our drugs work in the nervous system.

May 03, 2012 Targacept Reports First Quarter 2012 Financial Results April 25, 2012 Targacept Announces Reduction in Force and Plan to Focus Resources on Later-Stage Pipeline April 10, 2012 Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of TC-6987 in Asthma March 27, 2012 Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of TC-6987 March 20, 2012 AstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy Studies Do Not Meet Primary Endpoint, Regulatory Filing Will Not Be Pursued February 21, 2012 Targacept Reports Fourth Quarter and 2011 Financial Results January 05, 2012 Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s Disease